MedTrace Logo

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

NCT00232947 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2007-01-22

No results posted yet for this study

Summary

The goal of this study is to determine whether the immune responses induced by Fluviral, the investigational vaccine, are comparable to those induced by Fluzone, which is an influenza vaccine currently licensed in the U.S. The study focuses on persons 50 years old and over. In addition, the study will compare the rate of reactions to the two vaccines, and the general health of persons who receive them over the 42 days after immunization.

Conditions

Interventions

BIOLOGICAL

Influenza virus vaccine (Fluviral)

BIOLOGICAL

Influenza virus vaccine (Fluzone)

Sponsors & Collaborators

  • ID Biomedical Corporation, Quebec

    lead INDUSTRY

Principal Investigators

  • Nancy Bouveret, MD · ID Biomedical of Quebec

Study Design

Allocation
RANDOMIZED
Purpose
ECT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Completion
2006-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00232947 on ClinicalTrials.gov